Valuation: Allergy Therapeutics plc

Market Cap 427M 574M 502M 463M 805M 55.28B 822M 5.54B 2.18B 27.08B 2.15B 2.11B 93.25B P/E 2026 *
-8.43x
P/E 2027 * -
Enterprise Value 465M 625M 546M 504M 876M 60.18B 895M 6.03B 2.37B 29.48B 2.35B 2.3B 102B EV / Sales 2026 *
7.37x
EV / Sales 2027 * -
Free-Float
11.51%
Yield 2026 *
-
Yield 2027 * -
1 day+3.69%
1 week+0.30%
Current month-5.07%
1 month-10.13%
3 months-35.81%
6 months-44.30%
Current year-38.73%
1 week 6
Extreme 6
7.5
1 month 6
Extreme 6
8
Current year 6
Extreme 6
12.1
1 year 6
Extreme 6
12.1
3 years 1.2
Extreme 1.2
12.1
5 years 0.8
Extreme 0.8
40.5
10 years 0.8
Extreme 0.8
40.5
Manager TitleAgeSince
Chief Executive Officer 62 2009-08-31
Director of Finance/CFO - 2023-08-10
Corporate Officer/Principal 62 2026-01-28
Director TitleAgeSince
Director/Board Member 62 2009-08-31
Chairman 75 2011-01-03
Director/Board Member 69 2017-06-05
Date Insider Type Main position Quantity % Market Cap.
6/13/26 Free

Chief Financial Officer

2,300,000 0.0363%
3/12/26
ZQ Capital Ltd.
OthersCompany 150,925,926 2.4575%
3/12/26
ZQ Capital Ltd.
OthersCompany 1,993,473,455 32.4594%
Change 5-day change 1-year change 3-year change Capi.($)
+3.69%+0.30%-15.75%+254.74% 574M
-0.33%+1.83%+23.03%-6.22% 68.85B
+0.67%+0.93%+37.53%+198.53% 52.13B
+0.94%+39.60%+39.60%+39.60% 43.46B
+1.12%+0.35%-50.35%-52.35% 41.24B
-1.40%+3.43%+60.07%-26.01% 30.41B
-2.11%-9.45%+91.99%-49.58% 24.53B
+0.51%+0.46%+70.08%+91.96% 23.42B
-5.57%-0.84%-0.17%+174.11% 19.75B
-0.86%-1.99%+68.42%+124.39% 16.57B
Average -0.33%-0.70%+32.44%+74.92% 32.09B
Weighted average by Cap. -0.33%-0.07%+31.26%+47.60%

Financials

2026 *2027 *
Net sales 63M 84.75M 74.06M 68.4M 119M 8.16B 121M 818M 321M 4B 318M 311M 13.76B -
Net income -49.3M -66.32M -57.96M -53.53M -92.99M -6.39B -94.99M -640M -251M -3.13B -249M -244M -10.77B -
Net Debt 37.8M 50.85M 44.44M 41.04M 71.3M 4.9B 72.83M 491M 193M 2.4B 191M 187M 8.26B -
Logo Allergy Therapeutics plc
Allergy Therapeutics plc is a United Kingdom-based international commercial biotechnology company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum free immunotherapies that have the potential to cure disease. It sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional 10 countries. It sells both injectable and sublingual (oral) allergen-specific immunotherapies. Its pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. Its therapies are traded under various brand names depending on the market, such as Pollinex Quattro, Polligoid and TA Graser Top. Its commercial products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics and Acarovac Plus. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL, and VLP Peanut.
Employees
584
Date Price Change Volume
26-07-17 GBX 6.740 +3.69% 66,345
26-07-16 GBX 6.500 -4.41% 72,990
26-07-15 GBX 6.800 -8.11% 275,692
26-07-14 GBX 7.400 +8.82% 112,828
26-07-13 GBX 6.800 +1.19% 35,274
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0674GBP
Average target price
0.1300GBP
Spread / Average Target
+92.88%

Annual profits - Rate of surprise